Azilsartan/Chlorthalidone

DEA Class; Rx

Common Brand Names; Edarbyclor

Oral combination product containing angiotensin II receptor blocker (ARB) with a thiazide diuretic
Used for treatment of HTN in adults

Indicated for the treatment of hypertension, either alone or in combination with other antihypertensive agents.

Anuria

Coadministration with aliskiren-containing products in patients with diabetes

Dizziness (8.9%)

Fatigue (2%)

Hypotension (1.7%)

Syncope (0.3%)

Nausea

Rash, pruritus, angioedema

Loss of consciousness

Hyperuricemia

• Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving chlorthalidone or other thiazide diuretics

Hypotension in volume or salt depleted patients

• In patients with an activated renin-angiotensin system, symptomatic hypotension may occur after initiation of treatment; such patients are probably not good candidates to start therapy with more than one drug

Electrolytes

• Hypokalemia is a dose-dependent adverse reaction that may develop with chlorthalidone; Edarbyclor attenuates chlorthalidone-associated hypokalemia

Drug can cause fetal harm when administered to a pregnant woman; use of drugs that act on renin-angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death

There is limited information regarding presence of azilsartan in human milk, effects on breastfed infant, or on milk production; azilsartan is present in rat milk